NCT03113188已完成1 期
Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 3
- 主要终点
- Recommended dose
研究概览
简要总结
This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
详细描述
Multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors. The study will be conducted in two parts.
The first part of the study involves dose-escalation, in which successive cohorts of three patients (expanded up to six patients in the event of a dose-limiting toxicity (DLT) or safety concerns) will receive escalating doses of CBP501 and/or cisplatin until the maximum tolerated dose (MTD) is reached or RP2D defined, based on tolerability observed during the first 21 days of treatment and safety review of all available information by the Safety Monitoring Committee.
The second part of the study involves treatment of expansion cohorts of 10 evaluable patients each in pretreated metastatic exocrine pancreatic cancer and in microsatellite stable colorectal cancer to confirm the tolerability of treatment at the RP2D and evaluate preliminary evidence of anti-tumor activity in these indications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent obtained prior to initiation of any study-specific procedures and treatment;
- •Previously treated, pathologically confirmed, locally advanced or metastatic solid tumors with measurable disease for which cisplatin is a reasonable treatment option, including, but not limited to, non-small cell lung, mesothelioma, head & neck, ovarian, endometrial, breast, bladder, kidney, esophageal, gastric, colon, liver, gallbladder, cholangiocarcinoma, pancreas, soft tissue sarcoma, and osteosarcoma (for the expansion cohorts, only metastatic exocrine pancreatic cancer and microsatellite stable colorectal cancer are allowed). There is no limit on the number of prior lines of chemotherapy (including prior cisplatin), chemoradiotherapy, radiotherapy or investigational agents the patient can have received in order to be eligible, as long as cisplatin is a reasonable treatment option and all eligibility criteria are met, with the exception that a patient must not have received more than two prior lines incorporating anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade.
- •Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade therapy must have tolerated therapy with no evidence of grade 4 toxicity or an immune-related event (any grade) that required treatment discontinuation. Patients who experienced an endocrine related dysfunction are eligible, provided they are on stable hormone replacement therapy;
- •Male or female patients aged ≥ 18 years at time of informed consent;
- •ECOG Performance Status (PS) 0-1;
- •Life expectancy > 3 months;
- •Previous anticancer treatment must be discontinued at least 3 weeks prior to the initiation of study treatment (6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, except 8 weeks for bicalutamide);
- •Adequate bone marrow reserve, cardiac, liver, renal and metabolic function:
- •absolute neutrophil count (ANC) ≥ 1.5 x 109/L;
- •platelet count ≥ 100 x 109/L;
- •hemoglobin ≥ 9 g/dL;
- •white blood cell count (WBC) ≤ upper limit of normal (ULN);
- •creatinine phosphokinase isozymes CPK-MB and CPK-MM
- •serum troponin T levels within normal limits;
- •bilirubin ≤ 1.5 x ULN;
- •alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present);
- •INR ≤ 1.5 x ULN;
- •serum creatinine ≤ ULN or creatinine clearance ≥ 60 mL/min (by Cockroft & Gault formula or alternate calculation by 24hr urine collection);
- •serum potassium NCI-CTCAE version 4.03 Grade <2;
- •serum calcium NCI-CTCAE version 4.03 Grade <2;
- •serum magnesium NCI-CTCAE version 4.03 Grade <2;
- •Female patients of child-bearing potential must have a negative serum pregnancy test and use at least one form of contraception as approved by the investigator for 4 weeks prior to initiating study treatment and 4 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as "all female patients unless they are post-menopausal for at least 3 years or surgically sterile";
- •Male patients must use a form of barrier contraception approved by the investigator during the study and for 4 months after the last dose of study drug;
- •Ability to cooperate with study treatment and follow-up.
- •Exclusion Criteria
- •Radiation therapy to >30% of bone marrow prior to study entry;
- •Prior chemotherapy with nitrosoureas, prior mitomycin C cumulative dose ≥ 25 mg/m2, prior bone marrow transplant, or prior intensive chemotherapy with stem cell support;
- •Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the investigator (e.g., uncontrolled congestive heart failure, active infection, etc.);
- •Any previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 5 years of study entry;
- •Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient's compliance;
- •Evidence of peripheral neuropathy > grade 1 by NCI-CTCAE version 4.03;
- •Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to study entry;
- •Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception;
- •Known HIV, HBV, or HCV infection (excluding cured HCV infection);
- •Active CNS metastases; however, patients with CNS metastases will be eligible if they have been treated and are stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be off steroids;
- •Who require chronic systemic steroid therapy or on any other form of immunosuppressive medication;
- •Has received a live-virus vaccination within 30 days of planned treatment start;
- •With known risk factors for bowel perforation, i.e., history of diverticulitis, intra-abdominal abscess, intestinal obstruction, or abdominal carcinomatosis;
- •Has an active autoimmune disease or a documented history of autoimmune disease;
- •Has a history pneumonitis or interstitial lung disease.
排除标准
- 未提供
研究组 & 干预措施
CBP501, CDDP, Nivolumab
Experimental
CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
干预措施: CBP501 (Drug)
结局指标
主要结局
Recommended dose
时间窗: 21 days
Define the recommended doses (RP2D) of CBP501, cisplatin and nivolumab when administered in combination once every 21 days in patients with previously treated advanced solid tumors
次要结局
- Hint of efficacy in pretreated pancreatic and micro-satellite stable colorectal cancer patients(through study completion, an average of 6 month)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
1 期
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerAdvanced Clear Cell Renal Cell CarcinomaAdvanced Papillary Renal Cell CarcinomaAdvanced Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Clear Cell Renal Cell CarcinomaUnresectable Renal Cell CarcinomaNCT05122546City of Hope Medical Center31
已完成
1 期
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerAdvanced Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Renal Cell CarcinomaClear Cell Renal Cell CarcinomaNCT03829111City of Hope Medical Center30
终止
2 期
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%Non-small Cell Lung Cancer (NSCLC)NCT04139317Novartis Pharmaceuticals76
已完成
2 期
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)Metastatic Non-squamous Non Small Cell Lung CancerNCT00942825CanBas Co. Ltd.195
进行中（未招募）
1 期
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVAdvanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Kaposi SarcomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Lung Small Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Prostate CarcinomaAdvanced Renal Cell CarcinomaAdvanced Thyroid Gland Medullary CarcinomaAdvanced Triple-Negative Breast CarcinomaAdvanced Urothelial CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8HIV InfectionMetastatic Differentiated Thyroid Gland CarcinomaMetastatic Head and Neck CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Kaposi SarcomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Ovarian CarcinomaMetastatic Prostate CarcinomaMetastatic Renal Cell CarcinomaMetastatic Thyroid Gland Medullary CarcinomaMetastatic Triple-Negative Breast CarcinomaMetastatic Urothelial CarcinomaRecurrent Differentiated Thyroid Gland CarcinomaRecurrent Head and Neck CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Kaposi SarcomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaRecurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Cell CarcinomaRecurrent Thyroid Gland Medullary CarcinomaRecurrent Triple-Negative Breast CarcinomaRecurrent Urothelial CarcinomaRefractory Differentiated Thyroid Gland CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage III Lung Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8Advanced MelanomaNCT04514484National Cancer Institute (NCI)8